Breaking Down DESTINY-Gastric04 and MATTERHORN: Key Updates in Gastric Cancer
By Samuel Cytryn, MD - Last Updated: March 19, 2025Samuel Cytryn, MD, discusses two major recent developments in gastric and gastroesophageal cancer research: the DESTINY-Gastric04 and MATTERHORN trials. DESTINY-Gastric04 is a global phase III study comparing trastuzumab deruxtecan with ramucirumab and paclitaxel in the second-line setting, demonstrating promising survival benefits. The MATTERHORN trial evaluates the addition of durvalumab to perioperative FLOT chemotherapy for locally advanced gastric and gastroesophageal cancer, with early results indicating an improvement in event-free survival.
Advertisement
Advertisement
Related Posts
Dr. Janjigian reviews KEYNOTE-811, and how it led to the FDA approval of pembrolizumab for HER2-positive gastric cancers.
Of subtypes in KEYNOTE-059 and -061, HRD scores and TMB were highest in CIN and MSI-H subtypes, respectively.
Pembrolizumab previously received accelerated approval for this indication in 2021 based on interim results from KEYNOTE-811.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Dr. Albiges shares her thoughts on the FDA approval of subcutaneous nivo in gastric cancer and how it will impact practice.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.